EUROPEAN MODELS OF LONG-TERM CARE IN THE HOME AND COMMUNITY von Coleman, Barbara J.

Volltext

The role of the union in R&D von Coleman, B.J.

Volltext

Bell Revisited von Coleman, B. J.

Volltext

Interview ratings and later performance of PGCE students von Coleman, B.J.

Volltext

Inter-interviewer agreement in the selection of PGCE students von Coleman, B.J.

Volltext

The potential to increase soil carbon stocks through reduced tillage or organic material additions in England and Wales: A case study von Powlson, D.S., Bhogal, A., Chambers, B.J., Coleman, K., Macdonald, A.J., Goulding, K.W.T., Whitmore, A.P.

Volltext

Anti-angiogenic agents in ovarian cancer: past, present, and future von Monk, B J, Minion, L E, Coleman, R L

Volltext

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option von Buechel, M., Herzog, T.J., Westin, S.N., Coleman, R.L., Monk, B.J., Moore, K.N.

Volltext

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) von Pothuri, B., Blank, S.V., Myers, T.K., Hines, J.F., Randall, L.M., O'Cearbhaill, R.E., Slomovitz, B.M., Eskander, R.N., Alvarez Secord, A., Coleman, R.L., Walker, J.L., Monk, B.J., Moore, K.N., O'Malley, D.M., Copeland, L.J., Herzog, T.J.

Volltext

830P Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC) von Monk, B.J., Herzog, T., McGowan, T., De Rivas Otero, B., Gomez, J., Tanovic, A., Coleman, R.L.

Volltext

Saving the best treatment for last? von Coleman, R.L., Monk, B.J.

Volltext

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer von Mattie, Michael, Raitano, Arthur, Morrison, Kendall, Morrison, Karen, An, Zili, Capo, Linnette, Verlinsky, Alla, Leavitt, Monica, Ou, Jimmy, Nadell, Rossana, Aviña, Hector, Guevara, Claudia, Malik, Faisal, Moser, Ruth, Duniho, Steven, Coleman, Jeffrey, Li, Ying, Pereira, Daniel S, Doñate, Fernando, Joseph, Ingrid B J, Challita-Eid, Pia, Benjamin, Dennis, Stover, David R

Volltext

LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) w... von Monk, B.J., Oaknin, A., O'Malley, D.M., Wilson, M., Lorusso, D., Westin, S., Oza, A.M., Zagouri, F., Herzog, T.J., Mikheeva, O., Parkinson, C., Coleman, R.L., Lim, M.C., Chudecka-Glaz, A.M., Eskander, R.N., Bruchim, I., Ghamande, S., Despain, D., Fujiwara, K., Kristeleit, R.

Volltext

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial von Powell, M.A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L.M., Gropp-Meier, M., Stuckey, A., Boere, I., Gold, M.A., Segev, Y., Gill, S.E., Gennigens, C., Sebastianelli, A., Shahin, M.S., Pothuri, B., Monk, B.J., Buscema, J., Coleman, R.L., Slomovitz, B.M., Ring, K.L., Herzog, T.J., Balas, M.M., Grimshaw, M., Stevens, S., Lai, D.W., McCourt, C., Mirza, M.R.

Volltext

VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN... von Mirza, M.R., Chase, D., Slomovitz, B.M., Christensen, R.D., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L.M., Hanker, L.C., Stuckey, A., Boere, I.A., Gold, M., Gill, S.E., Monk, B.J., He, Z., Stevens, S., Coleman, R.L., Powell, M.A.

Volltext

Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis von Richardson, M.T., Kapp, D.S., Chan, J.E., Liang, S.Y., Mann, A.K., Monk, B.J., Herzog, T.J., Lakomy, D.S., Coleman, R.L., Chan, J.K.

Volltext

818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomiz... von Randall, L., O'Malley, D., Gunderson Jackson, C., Coleman, R.L., Hays, J., Moore, K.N., Naumann, R.W., Rocconi, R., Slomovitz, B., Tewari, K.S., Ancukiewicz, M., Ortuzar Feliu, W.I., Monk, B.J.

Volltext

A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of advanced-relapsed epithelia... von Monk, B.J., Herzog, T.J., Triantos, S., Wang, G., Shalaby, W.S.W., McGowan, T., Coleman, R.L.

Volltext

1030P - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabecte... von Monk, B.J., Herzog, T.J., Triantos, S., Maul, S., Wang, G., Valero, M J Pontes, McGowan, T., Shalaby, W.S., Coleman, R.L.

Volltext

Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T)... von Monk, B.J., Herzog, T.J., Triantos, S., Maul, S., Wang, G., Valero, M J Pontes, McGowan, T., Shalaby, W.S., Coleman, R.L.

Volltext